Boan Biotech Advances Phase II Trial for Novel Anti-CD25 Antibody Combination in NSCLC
核心洞察
China's Center for Drug Evaluation has accepted Boan Biotech's Phase II clinical trial application for BA1106 (anti-CD25 (搜索) antibody) combined with BA1104 (PD-1 (搜索) inhibitor) targeting driver gene-negative NSCLC patients.
BA1106 represents the first Chinese investigational non-IL-2 blocking anti-CD25 (搜索) antibody to enter clinical trials for solid tumors, offering a novel approach to enhance anti-tumor immunity.
Phase I results demonstrated encouraging efficacy signals across multiple solid tumor types with favorable safety profile, showing no dose-limiting toxicities up to 1.2 mg/kg.
Boan Biotech has achieved a significant regulatory milestone with China's Center for Drug Evaluation (CDE) accepting its Phase II clinical trial application for the combination of BA1106 and BA1104 in non-small cell lung cancer (NSCLC). The multicenter, single-arm, open-label trial will evaluate the efficacy, safety, and pharmacokinetic characteristics of this novel combination in driver gene-negative NSCLC patients.
Targeting an Underserved Patient Population
The trial focuses on driver gene-negative NSCLC patients, who represent approximately 40-50% of all NSCLC cases. This patient population faces significant treatment challenges, as NSCLC accounts for 85-90% of all lung cancer cases globally, making it one of the most common malignant tumors. Despite advances with immune checkpoint inhibitors, most patients in this category still develop drug resistance, leaving limited therapeutic options after disease progression.
Novel Mechanism of Action
BA1106 distinguishes itself as the first domestically developed anti-CD25 (搜索) antibody in China to enter clinical trials for solid tumors without blocking IL-2 signaling. The antibody targets regulatory T cells (Tregs), which are key immunosuppressive cells widely present in various solid tumors and associated with poor patient prognosis when present at high levels.
The innovative design of BA1106 features a "moderate" antibody-dependent cellular cytotoxicity (ADCC) effect and unique binding site that selectively targets CD25 (搜索)-highly-expressing Tregs. This selective approach depletes Tregs while increasing effector T cells (Teff) and avoiding interference with the IL-2 signaling pathway, thereby enhancing antitumor immune responses.
Promising Phase I Results
The Phase I clinical trial demonstrated encouraging efficacy signals across multiple solid tumor types, including lung adenocarcinoma, squamous cell lung cancer, and gastric cancer. Notably, all subjects in the study had previously received immune checkpoint inhibitor therapy and experienced disease progression, highlighting the potential of this combination in treatment-resistant cases.
Safety data from the Phase I trial showed favorable tolerability profiles for both BA1106 monotherapy and the combination with BA1104. The majority of treatment-related adverse events were Grade 1-2, and no dose-limiting toxicity events occurred during dose escalation. The maximum tolerated dose was not reached even at the 1.2 mg/kg dose group, providing strong support for advancing to Phase II development.
Strategic Development Plans
The company plans to actively advance Phase II clinical development of this combination regimen targeting both immunotherapy-naïve NSCLC patients and those who have progressed after previous immunotherapy. Beyond NSCLC, Boan Biotech intends to explore the therapeutic potential of this combination in other highly prevalent solid tumors, including gastric cancer.
The Phase I study has already demonstrated the synergistic potential of combining BA1106 with a PD-1 (搜索) inhibitor, with positive efficacy signals observed across multiple tumor types. Through precise regulation of Tregs, BA1106 achieves what the company describes as a favorable balance between efficacy and safety while enhancing antitumor immune responses.